Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This filing is a Form 6-K reporting the Quarterly Securities Report for the nine-month period ended December 31, 2019 (Fiscal Year 2019 Q3 YTD). The report was filed on February 13, 2020. The period includes the full integration of the Shire plc acquisition, which closed on January 8, 2019. Financial statements have been retrospectively adjusted to reflect the finalized purchase price allocation for the Shire acquisition.
Key Financial Metrics
| Metric (Nine-Month Ended Dec 31, 2019) | Value (JPY Billion) | YoY Change |
|---|---|---|
| Revenue | 2,519.5 | +82.6% |
| Operating Profit | 162.5 | -42.9% |
| Profit Before Tax | 56.0 | -73.1% |
| Net Profit | 42.7 | -74.0% |
| Net Cash from Operating Activities | 484.3 | +129.5% |
| Cash and Cash Equivalents (End of Period) | 568.3 | -19.0% |
| Total Debt (Bonds & Loans) | 5,221.8 | -9.2% |
Non-IFRS Metrics: Underlying Revenue Growth was -1.2%. Underlying Core Operating Profit Margin was 30.9%. Underlying Core EPS was 359.37 JPY.
Material Changes vs. Prior Period
- Revenue Surge: Reported revenue increased by 1,139.5 billion JPY, primarily driven by the inclusion of Shire products (1,155.5 billion JPY). On an underlying basis (excluding FX and divestitures), revenue declined 1.2% due to generic erosion and competitive pressure.
- Profit Decline: Net profit dropped significantly due to high non-cash amortization of intangible assets (329.1 billion JPY, up 314.6% YoY) related to the Shire acquisition and increased restructuring costs (103.6 billion JPY).
- Therapeutic Area Performance:
- GI: Revenue up 35.7% (ENTYVIO growth). Underlying growth +10.5%.
- Rare Diseases: Revenue up significantly due to Shire inclusion. Underlying revenue down 10.8% due to competition in hemophilia and a product recall of NATPARA.
- Neuroscience: Revenue up 348.4% (Shire inclusion). Underlying growth +4.6% driven by VYVANSE and TRINTELLIX.
- Oncology: Revenue up 3.7%. Underlying growth +6.8% led by NINLARO and ADCETRIS.
- Balance Sheet: Total assets decreased to 13,031.5 billion JPY. Total liabilities decreased to 8,155.3 billion JPY, driven by bond redemptions and FX impacts. Equity decreased to 4,876.2 billion JPY due to dividends and currency translation adjustments.
Outlook, Risks, and Unusual Items
- Debt Management: Takeda redeemed approximately 4.7 billion USD in senior notes during the period and issued 500 billion JPY in hybrid bonds. Financial covenants on certain loans were amended to replace a "profit before tax" restriction with a "net debt to EBITDA" ratio covenant.
- Divestitures: Completed the sale of XIIDRA (July 2019) and Axcelead Drug Discovery Partners (April 2019). Agreed to divest TACHOSIL and a portfolio of assets in the Middle East, Africa, and Russia/CIS.
- R&D Pipeline:
- Oncology: NINLARO maintenance therapy application submitted in Japan; Phase 3 trial for AL amyloidosis discontinued. ALUNBRIG showed strong efficacy in lung cancer.
- GI: FDA accepted BLA for subcutaneous ENTYVIO; received Complete Response Letter for UC indication. GATTEX pediatric indication approved.
- Rare Diseases: TAKHZYRO data presented showing long-term efficacy. NATPARA recalled in the US due to cartridge issues.
- Vaccines: Dengue vaccine (TAK-003) Phase 3 trial met primary endpoint with 80.2% efficacy.
- Legal: Settled patent infringement litigation with Roche regarding ENTYVIO. Settled generic litigation regarding MYDAYIS with Teva and Impax.
Investor Verification Checklist
- Underlying vs. Reported: Verify the distinction between reported revenue (inflated by Shire acquisition) and underlying revenue (-1.2% growth) to assess organic business health.
- Amortization Impact: Confirm the sustainability of operating margins given the 329.1 billion JPY in non-cash amortization charges.
- Debt Covenants: Review the amended financial covenants (Net Debt/EBITDA) to ensure compliance with new loan terms.
- Product Recalls & Litigation: Monitor the impact of the NATPARA recall and the resolution of the ENTYVIO patent settlement on future cash flows.
- Divestiture Proceeds: Track the completion and financial impact of the TACHOSIL and regional asset divestitures.